Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Inovio Pharmaceuticals Inc is a biotechnology business based in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Inovio Pharmaceuticals employs 317 staff and has a trailing 12-month revenue of around $2.1 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $1.73 |
|---|---|
| 52-week range | $1.38 - $7.77 |
| 50-day moving average | $2.18 |
| 200-day moving average | $3.01 |
| Wall St. target price | $4.20 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.54 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.725 from 2022-09-30
| 1 week (2022-09-23) | 0.88% |
|---|---|
| 1 month (2022-09-01) | -25.97% |
| 3 months (2022-07-01) | -8.73% |
| 6 months (2022-04-01) | -54.61% |
| 1 year (2021-10-01) | -74.25% |
|---|---|
| 2 years (2020-10-01) | -85.31% |
| 3 years (2019-10-01) | 1.97 |
| 5 years (2017-09-29) | 6.34 |
| Revenue TTM | $2.1 million |
|---|---|
| Gross profit TTM | $-247,465,566 |
| Return on assets TTM | -40.59% |
| Return on equity TTM | -87.99% |
| Profit margin | 0% |
| Book value | $1.20 |
| Market capitalisation | $414 million |
TTM: trailing 12 months
We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.
Inovio Pharmaceuticals's shares were split on a 1:4 basis on 5 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.
Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as $1.38 up to $7.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.817. This would suggest that Inovio Pharmaceuticals's shares are less volatile than average (for this exchange).
Inovio Pharmaceuticals, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp. , AstraZeneca, Beijing Advaccine Biotechnology Co. , Ltd.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
